Preview

Rational Pharmacotherapy in Cardiology

Advanced search

CYP2C19 PHARMACOGENETIC TESTING FOR PERSONALIZATION OF ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME IN ROUTINE CLINICAL PRACTICE

https://doi.org/10.20996/1819-6446-2017-13-6-771-775

Full Text:

Abstract

Aim. To study the use of CYP2C19 pharmacogenetic testing (PhGT) for personalization of antiplatelet therapy in patients with acute coronary syndrome (ACS) in routine practice.

Material and methods. The study included 103 patients with ACS without indications for long-term anticoagulant therapy, which underwent CYP2C19 PhGT aimed at antiplatelet therapy personalization.

Results. According to CYP2C19 genotyping the GG, GA, AA allelic variants were detected. CYP2C19*2 PhGT revealed that genotypes GG, GA and AA were carried by 76 (73.8%), 23 (22.3%) and 4 (3.9%) patients, respectively. Initially 86 (83.5%) patients received clopidogrel, 17 (16.5%) – ticagrelor. After therapy correction based on genotype GA and AA, the proportion of ticagrelor receiving patients increased from 25.9% to 55.5% (relative risk=0.172; 95% confidence interval 0.075-0.396; p<0.001). In 40.7% of patients who were poor clopidogrel metabolizers increased clopidogrel doses during maintaining therapy can be associated with the increased risk of bleeding.

Conclusion. PhGT results (detection of carriage of the CYP2C19*2 allele variant) was a significant predictor of antiplatelet therapy correction in ACS patients. Therapy personalization included the replacement of clopidogrel with ticagrelor or an increase in the clopidogrel maintenance dose to 150 mg per day, which did not affect significant clinical outcomes.

About the Authors

A. I. Akhmetova
Multidisciplinary Medical Center of the Bank of Russia
Russian Federation

Anna I. Akhmetova – MD, Internist, Department of Medical Care Quality Management 

Sevastopolsky prosp. 66, Moscow, 117593



E. B. Kleimenova
Multidisciplinary Medical Center of the Bank of Russia; Institute of Modern Information Technologies in Medicine, Federal Research Center “Computer Science and Control”, Russian Academy of Sciences
Russian Federation
Elena B. Kleimenova – MD, PhD, Head of Department of Medical Care Quality Management, Multidisciplinary Medical Center of the Bank of Russia; Deputy Director for Scientific and Clinical Work, Institute of Modern Information Technologies in Medicine, Federal Research Center “Computer Science and Control”, Russian Academy of Sciences


D. A. Sychev
Russian Medical Academy of Continuous Professional Education
Russian Federation

Dmitry A. Sychev – MD, PhD, Professor, Corresponding Member of the Russian Academy of Sciences, Head of Chair of Clinical Pharmacology and Therapy, Vice-Rector for Development and Innovation 

Barrikadnaya ul. 2/1-1, Moscow, 125993



O. V. Parshina
Multidisciplinary Medical Center of the Bank of Russia
Russian Federation

Olesya V. Parshina – Biologist, Department of Laboratory Research Methods

Sevastopolsky prosp. 66, Moscow, 117593



L. P. Yashina
Multidisciplinary Medical Center of the Bank of Russia; Institute of Modern Information Technologies in Medicine, Federal Research Center “Computer Science and Control”, Russian Academy of Sciences
Russian Federation
Lyubov' P. Yashina – PhD (Biology), Chief Expert, Department of Medical Care Quality Management, Multidisciplinary Medical Center of the Bank of Russia; Head of Laboratory of Informatization of Medical Technological Processes, Institute of Modern Information Technologies in Medicine


References

1. Roffi M., Patrono C., Collet J.-P. et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2016;37(3):267-315. doi: 10.1093/eurheartj/ehv320.

2. O’Gara P.T., Kushner F.G., Ascheim D.D. et al. 2013 ACCF/AHA Guideline for the Management of STElevation Myocardial Infarction. J Am Coll Cardiol. 2013;61(4):e78-140. doi: 10.1016/j.jacc.2012.11.019.

3. Ellis K.J., Stouffer G.A., McLeod H.L., Lee C.R. Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations. Pharmacogenomics. 2009;10(11):1799-817. doi: 10.2217/pgs.09.143.

4. Goluhova E.Z., Rjabinina M.N. Modern aspects of antiplatelet therapy. Kreativnaja Kardiologija. 2013;1:46-58. (In Russ.) [Голухова Е.З., Рябинина М.Н. Современные аспекты антиагрегантной терапии. Креативная Кардиология. 2013;1:46-58].

5. Mega J.L., Simon T., Collet J.P. et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010;304(16):1821-30. doi: 10.1001/jama.2010.1543.

6. Holmes M.V., Perel P., Shah T. et al. CYP2C19 Genotype, Clopidogrel Metabolism, Platelet Function, and Cardiovascular Events. A Systematic Review and Meta-analysis. JAMA. 2011;306(24):2704-14. doi: 10.1001/jama.2011.1880.

7. Mirzaev K.B., Sychev D.A., Karkishhenko V.N. et al. The frequency of polymorphic markers CYP2C19*2, CYP2C19*3, CYP2C19*17 among the Russian population and comparison of the prevalence of CYP2C19*2 in patients with coronary heart disease receiving clopidogrel therapy and healthy volunteers. Biomedicina. 2013;1:117-28. (In Russ.) [Мирзаев K.Б., Сычев Д.А., Каркищенко В.Н. и др. Частота полиморфных маркеров CYP2C19*2, CYP2C19*3, CYP2C19*17 среди русской популяции и сравнение распространенности CYP2C19*2 у пациентов с ишемической болезнью сердца, получающих терапию клопидогрелем, и здоровых добровольцев. Биомедицина 2013;1:117-28].

8. Cattaneo М. New P2Y(12) inhibitors. Circulation. 2010;121(1):171-9. doi: 10.1161/CIRCULATIONAHA.109.853069.

9. Hamm C.W., Bassand J.-P., Agewall S. et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2011;32(23):2999-3054. doi: 10.1093/eurheartj/ehr236.

10. Ruda M.Ja., Averkov O.V., Panchenko E.P. et al. Society for Emergency Cardiology. Diagnosis and treatment of patients without ST-segment acute coronary syndrome. Neotlozhnaja Kardiologija. 2016;2:26-62. (In Russ.) [Руда М.Я., Аверков О.В., Панченко Е.П. и др. Рекомендации Общества специалистов по неотложной кардиологии. Диагностика и лечение больных острым инфарктом миокарда без подъема сегмента ST электрокардиограммы. Неотложная Кардиология. 2016;2:26-62].

11. Levine G.N., Bates E.R., Bittl J.A. et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease. J Am Coll Cardiol. 2016;68(10):1082-115. doi: 10.1016/j.jacc.2016.03.513.

12. Amsterdam E.A., Wenger N.K., Brindis R.G. et al. 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: A Report of the American College of Cardiology American Heart Association Task Force on Practice Guidelines. Circulation. 2014;130:e344-e426. doi: 10.1161/CIR.0000000000000134.

13. Windecker S., Kolh P., Alfonso F. et al. 2014 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2014:35;2541-619. doi: 10.1093/eurheartj/ehu278.

14. Erlikh A.D., Gratsiansky N.A. On Behalf Of Record-Participants. “Record-3” Russian Register of acute coronary syndrome. Characteristics of patients and treatment up to hospital discharge. Kardiologiia. 2016;4:16-24. (In Russ.) [Эрлих А.Д., Грацианский Н.А. Российский регистр острого коронарного синдрома «РЕКОРД-3». Характеристика пациентов и лечение до выписки из стационара. Кардиология. 2016;4:16-24]. doi: 10.18565/cardio.2016.4.16-24.

15. Scott S.A., Sangkuhl K., Gardner E.E. et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther. 2011; 90(2):328-32. doi: 10.1038/clpt.2011.132.

16. Instructions for the use of a medicinal product for medical use Plavix. Avilble at: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=1b69e35a-d3ba-493f-a237-7af8a4ea0572&t=. Checked November 06, 2017. (In Russ.) [Инструкция по применению лекарственного препарата для медицинского применения Плавикс. Доступно на: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=1b69e35a-d3ba-493f-a237-7af8a4ea0572&t=. Проверено 06.11.2017].

17. Jneid H., Anderson J.L., Wright R.S. et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guideline. JACC. 2012;60:645-81. doi: 10.1016/j.jacc.2012.06.004.

18. Chen S., Zhang Y., Wang L. et al. Effects of Dual-Dose Clopidogrel, Clopidogrel Combined with Tongxinluo Capsule, and Ticagrelor on Patients with Coronary Heart Disease and CYP2C19*2 Gene Mutation After Percutaneous Coronary Interventions (PCI). Med Sci Monit. 2017;23:3824-30. doi: 10.12659/MSM.903054

19. Mehta S.R., Tanguay J.F., Eikelboom J.W. et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet. 2010;376(9748):1233-43. doi: 10.1016/S0140-6736(10)61088-4.


For citation:


Akhmetova A.I., Kleimenova E.B., Sychev D.A., Parshina O.V., Yashina L.P. CYP2C19 PHARMACOGENETIC TESTING FOR PERSONALIZATION OF ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME IN ROUTINE CLINICAL PRACTICE. Rational Pharmacotherapy in Cardiology. 2017;13(6):771-775. (In Russ.) https://doi.org/10.20996/1819-6446-2017-13-6-771-775

Views: 224


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)